Equities Analysts Offer Predictions for FENC Q1 Earnings

Fennec Pharmaceuticals Inc (NASDAQ:FENC) – Analysts at HC Wainwright increased their Q1 2025 earnings per share estimates for Fennec Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 11th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.13) for the quarter, up from their previous estimate of ($0.20). HC Wainwright currently has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at $0.02 EPS, FY2025 earnings at ($0.28) EPS and FY2026 earnings at $0.63 EPS.

Several other research analysts have also recently commented on FENC. Stephens upgraded shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 18th. Wedbush reissued an “outperform” rating and set a $13.00 target price on shares of Fennec Pharmaceuticals in a research note on Monday.

Fennec Pharmaceuticals Trading Up 1.6 %

FENC stock opened at $6.50 on Thursday. Fennec Pharmaceuticals has a 12-month low of $3.96 and a 12-month high of $11.49. The company has a market cap of $179.15 million, a price-to-earnings ratio of -64.99 and a beta of 0.36. The firm has a 50 day moving average of $6.39 and a 200-day moving average of $5.63.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Franklin Resources Inc. increased its stake in shares of Fennec Pharmaceuticals by 18.7% in the 3rd quarter. Franklin Resources Inc. now owns 14,799 shares of the company’s stock valued at $74,000 after acquiring an additional 2,330 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Fennec Pharmaceuticals by 31.6% during the 4th quarter. Wells Fargo & Company MN now owns 13,152 shares of the company’s stock worth $83,000 after acquiring an additional 3,155 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Fennec Pharmaceuticals by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 303,090 shares of the company’s stock worth $1,916,000 after acquiring an additional 3,792 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Fennec Pharmaceuticals by 12.9% in the 4th quarter. Rhumbline Advisers now owns 34,299 shares of the company’s stock worth $217,000 after buying an additional 3,911 shares during the last quarter. Finally, Barclays PLC boosted its holdings in shares of Fennec Pharmaceuticals by 13.9% in the 4th quarter. Barclays PLC now owns 35,672 shares of the company’s stock worth $225,000 after buying an additional 4,353 shares during the last quarter. Institutional investors own 55.51% of the company’s stock.

Insider Activity

In related news, Director Rosty Raykov sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $6.79, for a total transaction of $67,900.00. Following the transaction, the director now directly owns 68,725 shares of the company’s stock, valued at approximately $466,642.75. This trade represents a 12.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 31,186 shares of company stock worth $203,389 over the last quarter. 10.98% of the stock is currently owned by company insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.